Ocuphire Pharma, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
  • Product Pipeline
    • Overview
    • APX3330
    • APX2009
    • Phentolamine Ophthalmic Solution 0.75%
    • Scientific Posters and Publications
  • Clinical Trials
    • Overview
    • VEGA-2 Pivotal Phase 3 Trial of Phentolamine Ophthalmic Solution 0.75% in Presbyopia Enrolling
    • ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330 Completed
    • MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects Completed
    • MIRA-3 Completed
    • MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol Completed
    • LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol Completed
    • VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine Completed
  • Partnerships
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Ocuphire in the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents

Read Press Release

Events

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
  • Ocuphire in the News

Sidoti Virtual Conference Presentation

Mar 23, 2023
Audio
Webcast
Ocuphire Pharma, Inc.
© Ocuphire Pharma, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Terms of Use